Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Wednesday 05 September, 2007

XTL Biopharm Ltd

Correction: XTL to Present at the Arch Investme...


11:30am replaces the incorrect 11:30pm



      XTL Biopharmaceuticals to Present at the Arch Investment Conference      

Valley Cottage, New York, September 5, 2007 - XTL Biopharmaceuticals Ltd.
(NASDAQ: XTLB; LSE: XTL; TASE: XTL), a biopharmaceutical company engaged in the
acquisition, development and commercialization of therapeutics for the
treatment of unmet medical needs, particularly neuropathic pain and hepatitis
C, today announced that Ron Bentsur, the Company's Chief Executive Officer, is
scheduled to present at the Arch Investment Conference. Mr. Bentsur will
present an overview of the Company including a discussion of Bicifadine, the
Company's late-stage clinical compound for the treatment of neuropathic pain.
Mr. Bentsur's presentation will take place, tomorrow, Thursday, September 6,
2007 at 11:30 am Eastern Daylight Time, at the Warwick Hotel in New York City.

A live audio webcast of Mr. Bentsur's presentation will be available at: http:/
/www.informedinvestors.com/VC/ClientPage.asp?ID=45356.                         
                An archived version of the webcast will be available following
the conclusion of the live presentation.

ABOUT XTL BIOPHARMACEUTICALS LTD.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of
therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is
developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for
the treatment of diabetic neuropathic pain. XTL is also developing several
novel pre-clinical hepatitis C small molecule inhibitors.  XTL also has an
active in-licensing and acquisition program designed to identify and acquire
additional drug candidates. XTL is publicly traded on the NASDAQ, London, and
Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

Contact:

Ron Bentsur, Chief Executive Officer

Tel: +1-(845)-267-0707 ext. 225

                                                                               
                                                                    


 END


                                                                                                                                                                                                                                                         

a d v e r t i s e m e n t